A new vaccine to protect children from respiratory viruses.
A parainfluenza virus 5 (PIV5)-based bivalent vaccine for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV)
['FUNDING_R21'] · CYANVAC, LLC · NIH-10920481
This study is testing a new nose spray vaccine that could help protect young children from serious respiratory infections caused by RSV and HMPV, making it easier for them to stay healthy and breathe better.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CYANVAC, LLC (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-10920481 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a safe and effective intranasal vaccine using parainfluenza virus 5 (PIV5) to protect against respiratory syncytial virus (RSV) and human metapneumovirus (HMPV). These viruses are major causes of respiratory infections in young children, leading to serious conditions like bronchiolitis and pneumonia. The vaccine aims to stimulate the immune system to produce antibodies against both viruses, potentially reducing the incidence of severe respiratory illnesses in children. The approach is novel as it combines immunogenic components from both viruses into a single vaccine, which is administered through the nose for easier delivery.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under the age of 10, particularly those at risk for severe respiratory infections.
Not a fit: Patients who are older than 10 years or those with existing severe respiratory conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new vaccine that significantly reduces respiratory infections in children.
How similar studies have performed: Previous research has shown promise in developing vaccines using similar viral vectors, indicating potential for success in this approach.
Where this research is happening
ATHENS, UNITED STATES
- CYANVAC, LLC — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GINGERICH, MARIA CRISTINA — CYANVAC, LLC
- Study coordinator: GINGERICH, MARIA CRISTINA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute respiratory infection